Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2601
Immunovant
IMVT
$6.29B
| $884K | ﹤0.01% |
+36,300
| New | +$778K |
2020 Q2
0 quarters
|
|
|
SOL
2602
DELISTED
Emeren Group
SOL
| $884K | ﹤0.01% |
776,486
+32,135
| +4% | +$34.2K |
2015 Q1
21 quarters
|
|
2603
Harmonic Inc
HLIT
$1.2B
| $882K | ﹤0.01% |
185,599
+111,400
| +150% | +$623K |
2018 Q2
8 quarters
|
|
2604
Harte-Hanks
HHS
$33.2M
| $881K | ﹤0.01% |
289,944
+29,603
| +11% | +$69.9K |
2014 Q4
22 quarters
|
|
2605
Protara Therapeutics
TARA
$163M
| $879K | ﹤0.01% |
29,986
+4,100
| +16% | +$127K |
2016 Q4
14 quarters
|
|
|
ALR
2606
DELISTED
AlerisLife Inc
ALR
| $879K | ﹤0.01% |
225,373
+7,000
| +3% | +$25K |
2013 Q2
28 quarters
|
|
|
ICBK
2607
DELISTED
County Bancorp, Inc. Common Stock
ICBK
| $877K | ﹤0.01% |
41,895
+2,800
| +7% | +$57.1K |
2018 Q1
9 quarters
|
|
|
LJPC
2608
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $876K | ﹤0.01% |
+205,733
| New | +$1.25M |
2020 Q2
0 quarters
|
|
|
ONIT
2609
Onity Group
ONIT
$222M
| $875K | ﹤0.01% |
87,807
-2,853
| -3% | -$24.5K |
2016 Q2
16 quarters
|
|
|
LOAN
2610
Manhattan Bridge Capital
LOAN
$39.2M
| $871K | ﹤0.01% |
186,995
-14,536
| -7% | -$60.6K |
2014 Q4
22 quarters
|
|
|
QNRX
2611
Quoin Pharmaceuticals
QNRX
$9.04M
| $868K | ﹤0.01% |
13
+4
| +44% | +$231K |
2019 Q1
5 quarters
|
|
|
SGMA
2612
DELISTED
Sigmatron International
SGMA
| $868K | ﹤0.01% |
257,464
-2,400
| -0.9% | -$7.56K |
2013 Q2
28 quarters
|
|
2613
Advanced Micro Devices
AMD
$993B
| $867K | ﹤0.01% |
16,474
-3,951,752
| -100% | -$210M |
2019 Q3
3 quarters
|
|
2614
Destination XL Group
DXLG
$21.8M
| $863K | ﹤0.01% |
1,326,985
+961,174
| +263% | +$426K |
2018 Q3
7 quarters
|
|
|
SKYS
2615
DELISTED
Sky Solar Holdings, Ltd.
SKYS
| $863K | ﹤0.01% |
182,057
+71,711
| +65% | +$186K |
2018 Q3
7 quarters
|
|
2616
Intellia Therapeutics
NTLA
$1.83B
| $862K | ﹤0.01% |
+41,000
| New | +$697K |
2020 Q2
0 quarters
|
|
2617
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.54B
| $861K | ﹤0.01% |
+8,100
| New | +$829K |
2020 Q2
0 quarters
|
|
|
RESI
2618
DELISTED
Front Yard Residential Corporation Common Stock
RESI
| $860K | ﹤0.01% |
+98,800
| New | +$904K |
2020 Q2
0 quarters
|
|
|
AKRO
2619
DELISTED
Akero Therapeutics
AKRO
| $859K | ﹤0.01% |
+34,484
| New | +$788K |
2020 Q2
0 quarters
|
|
2620
Beasley Broadcasting Group
BBGI
$20.6M
| $858K | ﹤0.01% |
17,659
-185
| -1% | -$8.86K |
2013 Q4
26 quarters
|
|
|
PRVL
2621
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $858K | ﹤0.01% |
57,600
-21,205
| -27% | -$327K |
2020 Q1
1 quarter
|
|
|
SYBX
2622
DELISTED
Synlogic
SYBX
| $854K | ﹤0.01% |
28,030
+25,732
| +1,120% | +$822K |
2019 Q1
5 quarters
|
|
|
UBP
2623
DELISTED
Urstadt Biddle Properties Inc.
UBP
| $853K | ﹤0.01% |
84,900
-2,200
| -3% | -$23.9K |
2013 Q2
28 quarters
|
|
|
CPAH
2624
DELISTED
Counterpath Corp
CPAH
| $853K | ﹤0.01% |
169,155
+147,755
| +690% | +$468K |
2020 Q1
1 quarter
|
|
|
CTHR
2625
DELISTED
Charles & Colvard Ltd
CTHR
| $851K | ﹤0.01% |
116,517
+46,440
| +66% | +$333K |
2014 Q4
22 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.